Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Neomycin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources
PubMed2000

Effect of test techniques of perfusion of neomycin sulfate patch tests. A comparative study with visual assessments.

Effects of test techniques on neomycin patch test results have not been thoroughly investigated. This study focuses on effects of dose and application time of neomycin sulfate patch tests on test results. The effects are assessed both visually and by perfusion. 16 subjects positive to neomycin are retested with neomycin sulfate in various doses and vehicles applied with different application devices for variable time intervals. All subjects were tested with a serial-dose series for time intervals ranging from 3 to 96 h (4 days [D]). The results show very good agreement between perfusion assessments and positive and negative visual assessments of reactions; however, a gray zone was detected where reactions with variable perfusion were associated with visually questionable test responses. 1:27 serial dilutions and wide application time intervals show a positive response with perfusion assessments and partly with visual assessments. Regardless of reading technique, highest reactivity of reactions was detected at either 96 h (day [D] 4) or 168 h (D7) in each subject with minor exceptions, regardless of dose, vehicle, application device or application time. Some findings of the study support the idea that reactions with papules alone are positive tests. Possible effect of tapes and foils on test results are discussed.

Adult↗
PubMed1984

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia.

Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safety, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type II hyperlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

Adult↗
PubMed1997

The effects of bradykinin on K+ currents in NG108-15 cells treated with U73122, a phospholipase C inhibitor, or neomycin.

1. Bradykinin has multiple effects on differentiated NG108-15 neuroblastoma x glioma cells: it increases Ins(1,4,5)P3 production and intracellular Ca2+ concentration [Ca2+]i evokes a Ca2+ activated K+ current (IK(Ca)) and inhibits M current (IM). We studied the effect of the aminosteroid U73122 and the antibiotic neomycin, both putative blockers of phospholipase C (PLC), on these four bradykinin effects. 2. Preincubation with 1 or 5 microM U73122 for 15 min partly suppressed Ins(1,4,5)P3 generation and the increase in [Ca2+]i induced by 1 microM bradykinin. U73122 10 microM caused total and irreversible inhibition. The inactive analogue U73343 was without effect. 3. Resting levels of Ins(1,4,5)P3 were not affected. However, resting [Ca2+]i was increased by 10 microM U73122, but not by U73343. Individual cells responded to 10 microM U73122 with a small increase in [Ca2+]i, followed in some cells by a large further rise. 4. Pretreatment of whole-cell clamped cells with 1 microM U73122 for 30 min reduced the bradykinin-induced IK(Ca) to a fifth of its normal size. To suppress it totally, a 7-12 min pretreatment with 5 microM U73122 was required. Again, U73343 was without effect. 5. U73122 and U73343 at concentrations of 5-10 microM irreversibly decreased the holding current (Ih) which at a holding potential of -30 or -20 mV mainly flows through open M channels. The decrease was often preceded by a transient increase. 6. M current (IM) measured with 1 s pulses, was also decreased by 5-10 microM U73122 and U73343, but short applications of U73122 could cause a small increase. The bradykinin-induced inhibition of IM was not affected by U73122. 7. Preincubation with 1 or 3 mM neomycin for 15 min did not affect Ins(1,4,5)P3 generation and the increase in [Ca2+]i induced by bradykinin. Pretreatment with 3 mM neomycin for about 20 min diminished the bradykinin-induced IK(Ca) to a fifth of its normal size. 8. The four main conclusions drawn from the results are: (a) U73122 suppresses bradykinin-induced PLC activation and IK(Ca), but not IM inhibition. (b) This indicates that the transient outward current IK(Ca), but not the decrease of IM in response to bradykinin, is mediated by PLC. (c) U73122 itself inhibits IM and mobilizes Ca2+ from intracellular stores. (d) Externally applied neomycin is not an effective inhibitor of PLC-mediated signalling pathways in NG108-15 cells.

Animals↗
PubMed1986

Reversible binding of polymyxin B and neomycin to the solid part of faeces.

Previous studies have shown that polymyxin B and neomycin were bound to the solid part of human faeces. In the present study, the faecal binding of polymyxin B and neomycin was studied, using a wide range of concentrations of drugs and faecal dilutions. Up to 25 mg of polymyxin B and 15 mg of neomycin could bind to 1 g of faeces but the binding was found to be reversible. With faeces of rats it was found that polymyxin B was mainly bound to the non-bacterial part of faeces, whereas neomycin was bound to the bacterial as well as the non-bacterial part. The implications of the reversible binding of antibiotics to intestinal contents for selective decontamination are discussed.

Animals↗
PubMed1979

Influence of neomycin and metronidazole on colonic microflora of volunteers.

The influence on colonic microflora of neomycin and metronidazole alone, or in combination, was studied in volunteers taking a normal diet. Bacterial counts on daily faecal samples revealed that metronidazole had no influence on anaerobic faecal bacteria. Neomycin on the other hand, was effective against sensitive aerobes. However, the combination of neomycin and metronidazole profoundly reduced both aerobic and bacteria. Assay of faecal antibiotic concentrations showed that neomycin achieved high intraluminal levels while metronidazole was undetectable or present at low concentrations.

Bacteroides fragilis↗
PubMed2000

Efficacy of neomycin sulfate water medication on the control of mortality associated with colibacillosis in growing turkeys.

The objective of this investigation was to evaluate the efficacy, safety, and toxicity of neomycin sulfate (Neomix 325) water medication to control mortality associated with colibacillosis (Escherichia coli) in growing turkeys. One efficacy trial was conducted at five locations; each location included 2,880 sexed 21-d-old turkey poults that were naturally challenged with litter from turkey flocks that had colibacillosis. Between 5 and 7 d after challenge, and when mortality had reached 0.5%, poults were randomized within sex into three treatment groups of 0, 11, or 22 mg neomycin sulfate/kg body weight. In each location, each treatment was replicated 12 times with 40 poults per sex per replicate. All treatments were administered in the drinking water for 5 d. The pivotal decision criterion was mortality. Mortality was defined as 1) supported mortality (SM): positive microbial culture for E. coli and gross lesions, 2) diagnosed mortality (DM): diagnosed as associated with E. coli but not supported by lesions or positive microbiological cultures, 3) overall mortality (OM): mortality associated with E. coli or other microorganisms and miscellaneous reasons such as accidents (trampling or suffocations). Performance data (growth and feed utilization) also were measured and are reported without statistical analysis. Results from this efficacy study clearly demonstrated the effectiveness of neomycin sulfate against E. coli as measured by a reduction in mortality. In the target animal safety and toxicity study (done in conjunction with the efficacy study), neomycin sulfate in the drinking water at 66, 110, or 220 mg/kg per d for 15 d had no observable adverse effects on poult performance, as measured by feed or water consumption, body weight, gross pathology, or mortality.

Animal Nutritional Physiological Phenomena↗
PubMed1994

Disposition and bioavailability of neomycin in Holstein calves.

The disposition and absorption kinetics of neomycin were studied in healthy ruminating dairy calves (n = 6), approximately 3-months-old. The calves were treated with single intravenous (i.v.) (12 mg/kg), intramuscular (i.m.) (24 mg/kg), oral (p.o.) (96 mg/kg) and repeated p.o. (96 mg/kg, b.i.d., 15 1/2 days) doses of neomycin. A 3-week rest period was allowed between treatments A and B, and B and C. Baseline and serial venous blood samples were collected from each calf. Plasma concentrations of neomycin were determined by a high performance liquid chromatography procedure. The resulting data were evaluated by using compartmental pharmacokinetic models and nonlinear least squares regression analysis. The mean of some selected parameters were t1/2 lambda 3 7.48 +/- 2.02 h, Clt = 0.25 +/- 0.04 L/h/kg, Vd(ss) = 1.17 +/- 0.23 L/kg, and MRT = 4.63 +/- 0.87 h for the i.v. data and t1/2 = 11.5 +/- 3.8 h, MRTabs = 0.960 +/- 1.001 h, F = 127 +/- 35.2%, and Clt/F = 0.199 +/- 0.047 L/h/kg for the i.m. data, respectively. Only one calf absorbed neomycin to any significant degree (F = 0.0042) after a single p.o. dose. Selected mean parameters determined after repeated oral dosing were: F = 0.45 +/- 0.45%, Cmax = 0.26 +/- 0.37 microgram/ml, and tmax = 2.6 +/- 2.9 h. Terminal half-lives determined for the i.v. and i.m. treatments were considerably longer than those reported previously in the literature.

Animals↗
PubMed1995

Neurochemical evidence that [Ca2+]o antagonizes the effect of neomycin on acetylcholine release from mouse hemidiaphragm preparation: an attempt to assess the margin to safety.

Although the neuromuscular junction is the most thoroughly studied synapse of any type and has become the model of our understanding of synaptic transmission, some questions remain unanswered; e.g. there has been no direct assessment of the size of margin of safety. In this study the [Ca2+]o-dependent, quantally released acetylcholine measured by a neurochemical method, and the contraction of the mouse hemidiaphragm in response to phrenic nerve stimulation were recorded, and the effect of neomycin was studied. It was found that a much higher concentration of neomycin was needed to depress contractions, than to reduce acetylcholine release to the same extent, and that there was an inverse correlation between [Ca2+]o and the inhibitory effect of neomycin on acetylcholine release. Ninety percent of the release of acetylcholine had to be reduced by neomycin before any reduction in muscle responses could be seen. This indicates that the margin of safety is about 10. In conclusion, at the neuromuscular junction any reduction in ACh release, whatever the mechanism, first produces a reduction in the margin of safety. The nondepolarizing neuromuscular blocking agents block primarily the nicotinic receptors located on the postjunctional site. Many receptors have to be blocked before a reduction of muscle response is observed. This is probably the reason why unexpected clinical problems (e.g. recurarization) have been described when a patients has been treated with antibiotics, even though the dose of muscle relaxant injected was relatively low.

Acetylcholine↗
PubMed1990

Herpes simplex virus type-1 immediate-early gene expression and shut off of host protein synthesis are inhibited in neomycin-treated human epidermoid carcinoma 2 cells.

Infection of human epidermoid carcinoma-2 (HEp-2) cells by Herpes simplex virus type 1 (HSV-1) leads to significant activation of inositol phospholipid turnover after 15 min. The effect of neomycin, an inhibitor of inositol phospholipid turnover, has been investigated for its effect on HSV-1 multiplication in HEp-2 cells. HSV-1 multiplication is inhibited by neomycin. This inhibition is not due to a block of virus adsorption or penetration. Neomycin inhibits the expression of virus immediate-early genes, as well as expression of early genes and viral DNA synthesis. In neomycin-treated cells, the usual virion-associated shut off of host protein synthesis does not occur. These results indicate that the inositol phospholipid pathway is involved in immediate-early gene expression and shut off of host protein synthesis in HEp-2 cells.

Animals↗
PubMed2006

Effect of dried oregano leaves versus neomycin in treating newborn calves with colibacillosis.

Treatment with neomycin (as a positive control) and dried oregano leaves on mortality, number of days scouring and severity of scours due to Escherichia coli were examined in 30 Holstein calves. Calves were assigned to one of the treatments following clinical signs of diarrhoea (i.e. faecal score >2), and treated either with an oral solution of neomycin sulphate, to provide 10 mg neomycin sulphate per kg calf body weight per 24 h, or dried oregano leaves, to provide 10 mg oregano essential oil per kg calf body weight per 24 h. The number of scouring days, severity of scouring and mortality rates were similar between the treatments. This study indicates that dried oregano leaves administered as an oral solution to calves with diarrhoea may be as effective in the treatment of colibacillosis as neomycin.

Animals↗
PubMedDate not supplied

Further studies on neomycin and experimental hypertension.

Acute glucocorticoid (corticosterone) hypertension in the rate is significantly attenuated by neomycin administration (Honour 1981), as is ACTH-induced hypertension is the same species (Honour & Kent 1981) presumably by altering gut bacterial steroid metabolism. The effect on blood pressure of oral neomycin administration was therefore examined in hypertension resulting from administration of a variety of glucocorticoid hormones. Neomycin significantly attenuated the elevation of blood pressure following ACTH or corticosterone, as previously shown, or prednisolone 1 mg/day; it did not affect blood pressure in rats given dexamethasone 0.2 mg/day, or cortisol 4 mg twice daily. Since the differential effect of neomycin on hypertension parallels neither pressor nor glucocorticoid activity of the administered steroids we propose that it reflects different patterns of enterohepatic handling and metabolism.

Adrenocorticotropic Hormone↗
PubMed1976

Inhibition by neomycin of polyphosphoinositide turnover in subcellular fractions of guinea-pig cerebral cortex in vitro.

The addition of 10(-5) M to 10(-3) M neomycin to incubations of subcellular fractions of guineapig cerebral cortex increased the labelling of phosphatidylinositol phosphate and decreased the labelling of phosphatidylinositol diphosphate by [gamma-32P]ATP. The effect was observed in all subcellular fractions tested and depended on the cationic form of the antibiotic. Similar effects on lipid labelling were exerted by related aminoglycosidic antibiotics, by neamine, spermine and poly-L-lysine. Other neomycin fragments, antibiotics, local anesthetics or small polyamines were ineffective. Neomycin also inhibited the enzymatic hydrolysis of 32P-polyphosphoinositides. The addition of the drug to aqueous dispersions of these lipids increased the turbidity and lowered the pH of the suspensions. It is suggested that the effects of neomycin on polyphosphoinositide metabolism result from the formation of an ionic complex between the lipids and the antibiotic.

Adenosine Triphosphate↗
PubMed1984

Effects of neomycin on galactose absorption across rat jejunum.

The effects of neomycin sulphate on galactose absorption have been studied using in vivo and in vitro preparations of rat small intestine. Neomycin (10(-3)M) produced an increase in the maximum transport capacity (Jmax) for the active component of absorption in vivo. The apparent Kt for absorption was unaffected. The antibiotic caused a dose-dependent increase in the potential difference across the mucosal membrane (Vm) measured in vitro, a maximal effect being seen at a concentration of 10(-4)M. Furthermore, the magnitude of the depolarization induced by the addition of galactose (4 mM) to the mucosal fluid was enhanced by neomycin (10(-4)M). Phlorhizin (10(-4)M) abolished the galactose-induced depolarization in both the absence and presence of the antibiotic. It is concluded that neomycin increases the electrical driving force for Na+ during Na+-coupled galactose entry into the enterocyte.

Animals↗
PubMed1989

The nephrotoxic potential of neomycin in the horse.

Neomycin was administered intramuscularly to four normal adult horses at a dose rate of 10 mg/kg bodyweight every 12 h for 10 days (21 doses). The pharmacokinetic behaviour of neomycin with multiple dosing was characterised and a range of blood chemical and urinary parameters examined for evidence of nephrotoxicity. There was evidence of physical renal tubular injury (enzymuria and cylindriuria) within four days of neomycin administration but this subsided following cessation of treatment. No significant functional nephrotoxicity was detected. More severe nephrotoxicity might be expected in ill horses and it is recommended that several clinicopathological results be monitored serially in those horses receiving parenteral neomycin.

Alkaline Phosphatase↗
PubMed1979

Oral neomycin dosage schedules for suppression of ammonia production by bowel flora.

To better define a minimal but optimal dose of oral neomycin to suppress ammonia production by bowel flora, several dosage regimens were examined in normal healthy volunteers. Fecal urease activity was quantitatively determined and was used as an indirect measure of intrinsic ammonia production by bowel flora. Large doses of neomycin were found to exert inhibition of fecal urease for many days. There was considerable variation in enzymatic activity among subjects even after adjustments were made for protein content of the stool. Depending on the dose, there was a 1- to 3-day lag in neomycin effect on stool urease activity and several days of continued effect. The most effective regimen of those studied was a loading dose of 6 g of neomycin given in three divided doses on day 1, followed by 1 g twice daily.

Adult↗
PubMed1993

Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C.

Entry of herpes simplex virus (HSV) into cells is believed to be mediated by specific binding of envelope proteins to a cellular receptor. Neomycin specifically blocks this initial step in infection by HSV-1 but not HSV-2. Resistance of HSV-2 to this compound maps to a region of the genome encoding glycoprotein C (gC-2). We have studied the function of gC-2 in the initial interaction of the virus with the host cell, using HSV-2 mutants deleted for gC-2 and gC-2-rescued recombinants. Resistance to neomycin was directly linked to the presence of gC-2 within the viral genome. In addition, deletion of the gC-2 gene caused a marked delay in adsorption to cells relative to the wild-type virus. HSV-1 recombinants containing chimeric gC genes composed of HSV-1 and HSV-2 sequences were used to localize neomycin resistance within the N-terminal 223 amino acids of gC-2. This region of the glycoprotein comprises an important domain responsible for binding of HSV-2 to cell receptors in the presence of neomycin. A gC-2-negative mutant is still infectious, indicating that HSV-2 also has an alternative pathway of adsorption.

Animals↗
PubMed1977

Selection of multiresistant coliforms by long-term treatment of hypercholesterolaemia with neomycin.

Patients with hypercholesterolaemia are often treated with the antimicrobial agent neomycin. Such treatment is potentially dangerous, however, as it may favour the emergence of multiresistant, R-factor-carrying, enteric bacteria among the intestinal flora. In 11 out of 14 patients who had received neomycin for three months to eight years most of the faecal coliforms were resistant to at least four antimicrobial drugs and capable of transferring this resistance to others. In contrast, only one out of nine patients who were treated with other lipid-lowering drugs had resistant bacteria in their faeces. Neomycin may cause multiresistant strains to emerge because, like tetracycline, it forms high concentrations in the gut. Long-term treatment of non-infectious conditions like hypercholesterolaemia with neomycin is potentially dangerous not only to the patient but also to the community because of the creation of a reservoir of multiresistant organisms.

Drug Resistance, Microbial↗
PubMed1978

Oral administration of neomycin to chickens experimentally infected with Salmonella typhimurium.

Groups of healthy chickens with a light experimental Salmonella typhimurium infection were fed on a diet containing 225 g per ton (1016 kg) of neomycin for two days. This brought about only a slight reduction in the incidence of chickens that were excreting S typhimurium in their faeces. Examination of caecal contents two days after the cessation of treatment revealed the neomycin had not had any effect in eliminating infection. In one experiment, the neomycin administration resulted in the emergence of enormous populations of Escherichia coli in the alimentary tract of treated chickens that possessed multiple antibiotic resistance of the transmissible type. For these reasons the practice of feeding broiler chickens on diets containing neomycin immediately before slaughter should be actively discouraged.

Administration, Oral↗